Celadon Pharmaceuticals Share Discussion Threads

[dpeach] 12/2/2009 09:00

Think JLC will seriously have to consider the 'DIVIDEND' option

[stemis] 12/2/2009 08:45

Yes I must admit I'm out as well.

I don't think the statement is particularly bad. Last year Celsis did an EPS of 30.53c. Modest growth? 32c? That would still be EPS of 22.5p (at 1.4232 current xch rate). Forecast is 23.44p so hardly much (if any) of a profit warning.

The problem is I would see any risk being downside, other than sterling falling or some corporate action re outsourced lab services, and therefore there seems little catalyst to take the share price upwards. I'd rather have the cash at the moment than parked earning no return in a potentially illiquid Celsis.

[dpeach] 12/2/2009 08:34

Riv I read it as quite positive (considering the times we live in), difficult 3rd quarter but core business improving and decision on A&D being made. Also just checking different brokers and all seem to be offering high end 'Bid' prices

[dpeach] 12/2/2009 08:28

well at least it's a very candid assessment - IVT, Rapid detection to continue growth... A&D being examined and IMHO if expansion current contracts / new contracts don't come through think will off load.

[rivaldo] 12/2/2009 08:20

Must admit I've sold most of mine. I didn't like the sound of the "modest" growth or the overall tone. I just thought that knowing CEL it'll drift down again, maybe even to 140p, without a positive catalyst - today's RNS just wasn't positive enough imo.

Good luck though - CEL remains cheap and I'm hoping to slowly buy back in depending on timing and price (I was surprised to be able to sell so easily at a decent price, so maybe I've misjudged things).

[dpeach] 12/2/2009 08:06

looks like we may have a dip down to the trend line to around 166p

[dpeach] 12/2/2009 08:00

what do we think

CELSIS INTERNATIONAL PLC
("Celsis", "the Company" or "the Group")


Interim Management Statement


12 February 2009: Celsis International plc, the life sciences products and
laboratory services company, today provides its Interim Management Statement for
the third quarter ended 31 December 2008.


Throughout the third quarter Celsis continued to demonstrate momentum in its
core businesses, despite the global economic contraction. Even with slightly
slower trading due to the uncertainties facing many of its key customers at the
end of 2008, early January indicators reflect strengthened trading. The Group
believes that for the year as a whole it will sustain its revenue position and
deliver modest profit growth with continued stronger performances by its core
Rapid Detection and In Vitro Technologies product divisions.


The Celsis Rapid Detection division, which provides rapid microbial testing
systems used to reduce the time and cost to manufacture products, has continued
to generate solid reagent and consumable growth following its strong first half
performance. Instrument sales which rely on capital equipment budgeting did slow
at the end of the calendar year as customers' budgets became more constrained,
but have since picked up in the fourth quarter. It is anticipated that the
division will finish the year positively as its customer base, consisting of
some of the world's leading pharmaceutical and consumer product companies,
remains strongly focused on cost savings.


The Celsis In Vitro Technologies (Celsis IVT) division, which provides in vitro
testing products to the pharmaceutical industries to reduce the time and cost of
drug discovery and development, is expected to deliver positive growth for the
year despite seeing a slower third quarter due to tightened year end budgets
throughout the industry. The division has a healthy order book and marketing
plans are in place to secure growth across all market segments.


The Celsis Analytical and Development Services division, which provides
outsourced laboratory services to the pharmaceutical industry, has seen a slower
third quarter and is expected to complete the year down on last year's
performance. Both Analytical and Development Services teams are working to
expand existing and generate new contracts through the end of the financial
year. A review which examines several strategic alternatives for the laboratory
services businesses is currently being undertaken by the Board.

[relwood] 11/2/2009 16:42

As Rivaldo said 'Hopefully tomorrow'

[dpeach] 11/2/2009 15:55

down up, late recovery

[rivaldo] 09/2/2009 20:59

Hopefully tomorrow :o))

Interesting...



"February 09, 2009 03:00 PM Eastern Time
Promega and Celsis In Vitro Technologies to Offer More Reliable Solutions
for ADME/Tox Testing in Primary Hepatocytes

MADISON, Wis.--(BUSINESS WIRE)--Promega Corp. and Baltimore, Md.-based Celsis In Vitro Technologies (Celsis IVT) will take the trial and guess work out of ADME/Tox testing in primary hepatocytes. Promega will co-market their bioluminescent ADME-Tox assays with Celsis' extensive line of high quality cryopreserved plateable hepatocytes. Under the agreement, Celsis will pre-qualify lots of cryoplateable hepatocytes for use with specific P450-Glo CYP Assays to study cytochrome P450 gene induction and inhibition. In addition, Celsis will also validate cryopreserved lots of hepatocytes for use with Promega GSH-Glo Glutathione Assay for investigating mechanisms of hepatotoxicity.

"Combining validated biologic components with Promega's ultra-sensitive and dynamic luminescence assay detection technology is a significant benefit to scientists," said Philip M. Vorwald, vice president and general manager of Celsis IVT. "Our research has confirmed the higher predictive value and accuracy of the combined assay for identifying adverse side-effects in new chemical entities," he said. "Plus, it's significantly faster than traditional studies."

Determining whether a particular lot of hepatocytes will work for a given application is time-consuming and costly. Much of the effort involves trial and error. Even when a suitable lot of hepatocytes is identified, current LC/MS technologies for measuring gene expression, enzyme activity or metabolite formation are expensive or involve lengthy incubations times that often require several days to process. This collaborative effort between Promega and Celsis IVT will enable scientists to quickly and easily identify and select both products that have been validated to work together, saving valuable time and resources, increasing efficiency and leading to the faster development of safe drugs.

"Secondary screeners in particular are looking for validated ADME/Tox solutions that are more predictive." said Andy Bertera, vice president of marketing at Promega. "Having our ADME/Tox reagents pre-qualified for use with Celsis IVT's extensive line of cryoplateable hepatocytes provides the kind of ease and quality to scientists that is always our goal at Promega. This collaboration will take the guesswork out of ADME testing using primary hepatocyte."

The companies are collaborating on scientific presentations and publications demonstrating effective applications of the validated tools for ADME/Tox studies.

About Promega

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company's 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 14 countries and over 50 global distributors. For more information about Promega, visit www.promega.com."

[dpeach] 09/2/2009 17:19

update Tuesday or Thursday?

[dpeach] 09/2/2009 15:09

someone has just rolled over 205,000 shares - sold then re bought

[boadicea] 05/2/2009 20:36

Well and truly out of the triangle and should begin mapping the upper side of an uptrend channel (lower side already in place.) We can probably expect a pull-back to the lower side at some stage (end-of-financial-year effects perhaps) but if the two sides are to be parallel there could be upside to the mid or upper 180's from here before that happens.

By end March, lower side will be around 170p. A pre-close statement around that date should set the trend from there.

[churchtower] 05/2/2009 13:18

This break through 169/170 is good news. There is an obvious reverse head and shoulders pattern which has developed since April 2008. The neckline at 169/170 gives a measureable target of 210. Any retreat to that neckline which then provided support would be even more encouraging. The next few weeks will be interesting. I continue to maintain a strong hold.

[stemis] 05/2/2009 13:16

I see Edison are now forecasting EPS of 25.44p for 2008/9 reducing the P/E to 6.8, falling to 6.3 in 2009/10. With net cash of $870k at 30 September, the balance should build up quite nicely in the absence of a dividend.

[dpeach] 05/2/2009 12:52

good folk, i've got 150,000 they can have for £3

[rivaldo] 05/2/2009 12:36

I see someone was rather keen and paid 178p this morning for 5,582 shares.

[dpeach] 05/2/2009 11:02

Riv, looks like a little resistance line........but back up, onwards and forwards..

[rivaldo] 05/2/2009 09:15

New highs now...looking rather good.

Agreed about the divi boadicea, a fixed sum of dollars gives a lot more divi now than it did a few months ago (though it does set a precedent for the future assuming the pound ever recovers).

I suppose CEL would say that with IVT now fully integrated, and with many cheap, struggling targets out there in this market, their cash is better spent long-term on making further company-changing acquisitions without dilution.

The latter does make sense unless CEL really pay a meaningful divi, rather than just a sop, which would attract heavyweight fund interest. And/or whether CEL's share price advances to a level where share issues for acquisition can be made at a reasonable price.

[boadicea] 04/2/2009 23:39

The reasons previously given of preserving cash for possible expansion, esp by acquisition, were valid at the time. However, it would require a much smaller amount of cash to pay a dividend and, given a boosted sp, could enable acquisitions to be made mainly (or entirely) with paper.
It avoids undesirable (probably unavailable) debt loading and existing holders will happily agree if eps is not diluted.

There are many 'cheap' companies now in the market - AIM in particular. I am in no position, however, to judge which (if any) of them would make a good fit with CEL.

[sll] 04/2/2009 21:34

Smart point, boad, why not feed that thought in via Robyn Lalonde? You put it so compellingly, steve

[wywcu1] 04/2/2009 19:24

boadicea, fully agree with your sentiments. The divi. is very important in these very grim days.

[boadicea] 04/2/2009 18:07

Something that companies like CEL might now find it worth bearing in mind is that a divi giving a return comparable to what one can currently get on bank and BS deposits (i.e. 1 or 2%) would no longer be much of a burden to them.

The number of companies in CEL's relatively fortunate position is fairly limited and as such there could be a brisk demand for their shares as investors start to think ahead to the market's recovery phase. It would do no harm to attract a bit of positive attention.

[dpeach] 04/2/2009 16:06

hopefully get a close above 170p, seems like somethings happening in the background...